Skip to content

Arbutus Biopharma Corporation ABUS Equity Method Investments

Equity Method Investments at other companies

Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$332.97M+52.6%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$32.5M+0.6%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$12.79M+19.5%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$31.52M
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$20.57M+0.1%

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$871.14M+32.6%
Enterprise value$848.07M+36.6%
P/E5.4×
P/S4.6×-98.0×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0.0×
Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:EquityMethodInvestments.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's equity method investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arbutus Biopharma Corporation's equity method investments?
Arbutus Biopharma Corporation (ABUS) reported equity method investments of $0 in Q1 2026.
What does equity method investments mean?
Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.